Postpartum endometritis
Postpartum endometritis
Author:
Katherine T Chen, MD, MPH
Section Editor:
Vincenzo Berghella, MD
Deputy Editor:
Vanessa A Barss, MD, FACOG
Literature review current through: Mar 2024.
This topic last updated: Feb 20, 2024.

INTRODUCTION

Postpartum (puerperal) endometritis refers to a postpartum infection of the decidua (ie, pregnancy endometrium) that can affect all layers of the uterus. It is a common cause of postpartum fever and uterine tenderness and 10- to 30-fold more common after cesarean than vaginal birth. Most infections are mild and resolve with antibiotic therapy; however, in a minority of patients, the infection extends into the peritoneal cavity potentially resulting in peritonitis, intraabdominal abscess, or sepsis. Rare patients develop necrotizing myometritis, necrotizing fasciitis of the abdominal wall, septic pelvic thrombophlebitis, or toxic shock syndrome.

Endometritis after a vaginal or cesarean birth will be discussed here. Endometritis in patients who have had a pregnancy termination or spontaneous pregnancy loss and those who have not been recently pregnant is reviewed separately. (See "Overview of pregnancy termination", section on 'Infection/retained products of conception' and "Retained products of conception in the first half of pregnancy", section on 'Medically stable patients with endometritis' and "Endometritis unrelated to pregnancy".)

MICROBIOLOGY

Postpartum endometritis is typically a polymicrobial infection involving a mixture of two to three aerobes and anaerobes from the lower genital tract. Microbiology is similar to that of chorioamnionitis [1]. In a study of 55 antibiotic-naive patients with well-defined postpartum endometritis who had endometrial cultures obtained with a triple-lumen catheter (to reduce the risk of contamination from organisms on the cervix), 51 (93 percent) had an endometrial isolate and seven (13 percent) had a blood isolate [2]. Bacterial findings included:

At least one facultative or one anaerobic bacterial species – 42 of 51 (82 percent).

Genital mycoplasmas – 39 of 51 (76 percent).

Disclaimer: This generalized information is a limited summary of diagnosis, treatment, and/or medication information. It is not meant to be comprehensive and should be used as a tool to help the user understand and/or assess potential diagnostic and treatment options. It does NOT include all information about conditions, treatments, medications, side effects, or risks that may apply to a specific patient. It is not intended to be medical advice or a substitute for the medical advice, diagnosis, or treatment of a health care provider based on the health care provider's examination and assessment of a patient's specific and unique circumstances. Patients must speak with a health care provider for complete information about their health, medical questions, and treatment options, including any risks or benefits regarding use of medications. This information does not endorse any treatments or medications as safe, effective, or approved for treating a specific patient. UpToDate, Inc. and its affiliates disclaim any warranty or liability relating to this information or the use thereof. The use of this information is governed by the Terms of Use, available at https://www.wolterskluwer.com/en/know/clinical-effectiveness-terms. 2024© UpToDate, Inc. and its affiliates and/or licensors. All rights reserved.
Loading
Please wait